New research findings published in Science Advances (November 2022), help explain the progression of Alzheimer-related dementia in each patient. The findings outline a biological classification system that predicts disease severity.
COVID-19 has had a lasting global health impact that continues to challenge the health care system.
For the third time, Sanford Burnham Prebys has been selected by the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., supporting the NCI Experimental Therapeutics (NExT) Program as a Center for the Chemical Biology Consortium (CBC).
The Howard Hughes Medical Institute (HHMI) has selected Ian Maze, PhD, Associate Professor of Neuroscience, and Pharmacological Sciences, at the Icahn School of Medicine at Mount Sinai, as an HHMI Investigator.
Recent discoveries by two research teams in the Ira A. Fulton Schools of Engineering at Arizona State University are advancing the field of synthetic biology. Results from a research collaboration between the lab groups of Assistant Professor Xiaojun Tian and Associate Professor have revealed novel ways that engineered gene circuits interact with biological host cells.
A Rutgers-led team has created better biosensor technology that may help lead to safe stem cell therapies for treating Alzheimer’s and Parkinson’s diseases and other neurological disorders. The technology, which features a unique graphene and gold-based platform and high-tech imaging, monitors the fate of stem cells by detecting genetic material (RNA) involved in turning such cells into brain cells (neurons), according to a study in the journal Nano Letters.
An ecologist from Stony Brook University, a theoretical physicist from University of Colorado Boulder and a chemical biologist from Harvard University Three female scientists have been named Laureates of the Blavatnik National Awards for Young Scientists, each receiving $250,000, the…